These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 11912002

  • 1. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis.
    Heesen C, Gold SM, Raji A, Wiedemann K, Schulz KH.
    Psychoneuroendocrinology; 2002 May; 27(4):505-17. PubMed ID: 11912002
    [Abstract] [Full Text] [Related]

  • 2. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS.
    Then Bergh F, Kümpfel T, Trenkwalder C, Rupprecht R, Holsboer F.
    Neurology; 1999 Sep 11; 53(4):772-7. PubMed ID: 10489039
    [Abstract] [Full Text] [Related]

  • 3. Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial.
    Then Bergh F, Kümpfel T, Grasser A, Rupprecht R, Holsboer F, Trenkwalder C.
    J Clin Endocrinol Metab; 2001 Apr 11; 86(4):1610-5. PubMed ID: 11297592
    [Abstract] [Full Text] [Related]

  • 4. Hyperstable arousal regulation in multiple sclerosis.
    Stoppe M, Meyer K, Schlingmann M, Olbrich S, Then Bergh F.
    Psychoneuroendocrinology; 2019 Dec 11; 110():104417. PubMed ID: 31546115
    [Abstract] [Full Text] [Related]

  • 5. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers.
    Sher L, Oquendo MA, Burke AK, Cooper TB, Mann JJ.
    J Affect Disord; 2013 Dec 11; 151(3):1108-12. PubMed ID: 23866302
    [Abstract] [Full Text] [Related]

  • 6. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.
    Gold SM, Raji A, Huitinga I, Wiedemann K, Schulz KH, Heesen C.
    J Neuroimmunol; 2005 Aug 11; 165(1-2):186-91. PubMed ID: 15935481
    [Abstract] [Full Text] [Related]

  • 7. Correlates of cognitive dysfunction in multiple sclerosis.
    Heesen C, Schulz KH, Fiehler J, Von der Mark U, Otte C, Jung R, Poettgen J, Krieger T, Gold SM.
    Brain Behav Immun; 2010 Oct 11; 24(7):1148-55. PubMed ID: 20621641
    [Abstract] [Full Text] [Related]

  • 8. Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis.
    Grasser A, Möller A, Backmund H, Yassouridis A, Holsboer F.
    Exp Clin Endocrinol Diabetes; 1996 Oct 11; 104(1):31-7. PubMed ID: 8750568
    [Abstract] [Full Text] [Related]

  • 9. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
    Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O'Keane V.
    J Clin Endocrinol Metab; 2001 Aug 11; 86(8):3545-54. PubMed ID: 11502777
    [Abstract] [Full Text] [Related]

  • 10. Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis.
    Kümpfel T, Then Bergh F, Friess E, Uhr M, Yassouridis A, Trenkwalder C, Holsboer F.
    Neuroendocrinology; 1999 Dec 11; 70(6):431-8. PubMed ID: 10657736
    [Abstract] [Full Text] [Related]

  • 11. Associations between cognitive performance and cortisol reaction to the DEX/CRH test in patients recovered from depression.
    Behnken A, Bellingrath S, Symanczik JP, Rieck MJ, Zavorotnyy M, Domschke K, Arolt V, Zwanzger P.
    Psychoneuroendocrinology; 2013 Mar 11; 38(3):447-54. PubMed ID: 22840287
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients.
    Binder EB, Künzel HE, Nickel T, Kern N, Pfennig A, Majer M, Uhr M, Ising M, Holsboer F.
    Psychoneuroendocrinology; 2009 Jan 11; 34(1):99-109. PubMed ID: 18829172
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II.
    Lammers CH, Garcia-Borreguero D, Schmider J, Gotthardt U, Dettling M, Holsboer F, Heuser IJ.
    Biol Psychiatry; 1995 Dec 15; 38(12):803-7. PubMed ID: 8750038
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
    Owashi T, Otsubo T, Oshima A, Nakagome K, Higuchi T, Kamijima K.
    Psychoneuroendocrinology; 2008 Feb 15; 33(2):152-61. PubMed ID: 18068306
    [Abstract] [Full Text] [Related]

  • 19. The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression test.
    Deuschle M, Schweiger U, Gotthardt U, Weber B, Körner A, Schmider J, Standhardt H, Lammers CH, Krumm B, Heuser I.
    Biol Psychiatry; 1998 May 15; 43(10):762-6. PubMed ID: 9606531
    [Abstract] [Full Text] [Related]

  • 20. Sleep deprivation and hypothalamic-pituitary-adrenal (HPA) axis activity in depressed patients.
    Schüle C, Baghai T, Zwanzger P, Minov C, Padberg F, Rupprecht R.
    J Psychiatr Res; 2001 May 15; 35(4):239-47. PubMed ID: 11578642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.